[go: up one dir, main page]

FR2951169B1 - Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) - Google Patents

Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Info

Publication number
FR2951169B1
FR2951169B1 FR0957070A FR0957070A FR2951169B1 FR 2951169 B1 FR2951169 B1 FR 2951169B1 FR 0957070 A FR0957070 A FR 0957070A FR 0957070 A FR0957070 A FR 0957070A FR 2951169 B1 FR2951169 B1 FR 2951169B1
Authority
FR
France
Prior art keywords
pkb
pyrimidin
dihydro
oxo
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0957070A
Other languages
English (en)
Other versions
FR2951169A1 (fr
Inventor
Jean Christophe Carry
Victor Certal
Frank Halley
Andreas Karlsson
Laurent Schio
Fabienne Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0957070A priority Critical patent/FR2951169B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to MEP-2014-62A priority patent/ME01885B/me
Priority to HK12109790.9A priority patent/HK1169110B/xx
Priority to ARP100102350A priority patent/AR077364A1/es
Priority to PCT/FR2010/051375 priority patent/WO2011001114A1/fr
Priority to PT107420143T priority patent/PT2448927E/pt
Priority to CA2767064A priority patent/CA2767064C/fr
Priority to CN201080039214.XA priority patent/CN102548970B/zh
Priority to HRP20140478AT priority patent/HRP20140478T1/hr
Priority to AU2010267816A priority patent/AU2010267816B2/en
Priority to JP2012518120A priority patent/JP5680638B2/ja
Priority to MX2012000094A priority patent/MX2012000094A/es
Priority to SG2011097938A priority patent/SG177469A1/en
Priority to KR1020127002839A priority patent/KR20120106714A/ko
Priority to SI201030607T priority patent/SI2448927T1/sl
Priority to MYPI2011006377 priority patent/MY153042A/en
Priority to MA34593A priority patent/MA33501B1/fr
Priority to PE2012000004A priority patent/PE20120640A1/es
Priority to DK10742014.3T priority patent/DK2448927T3/da
Priority to EA201270111A priority patent/EA021088B1/ru
Priority to NZ597579A priority patent/NZ597579A/xx
Priority to EP10742014.3A priority patent/EP2448927B1/fr
Priority to RS20140306A priority patent/RS53317B/sr
Priority to SG10201402867TA priority patent/SG10201402867TA/en
Priority to PL10742014T priority patent/PL2448927T3/pl
Priority to ES10742014.3T priority patent/ES2464125T3/es
Priority to UY0001032755A priority patent/UY32755A/es
Priority to TW99121906A priority patent/TWI466883B/zh
Publication of FR2951169A1 publication Critical patent/FR2951169A1/fr
Application granted granted Critical
Publication of FR2951169B1 publication Critical patent/FR2951169B1/fr
Priority to CR20110703A priority patent/CR20110703A/es
Priority to DO2011000407A priority patent/DOP2011000407A/es
Priority to US13/338,011 priority patent/US8791255B2/en
Priority to CO11180700A priority patent/CO6480974A2/es
Priority to IL217295A priority patent/IL217295A/en
Priority to HN2011003482A priority patent/HN2011003482A/es
Priority to IL217321A priority patent/IL217321A0/en
Priority to CL2012000003A priority patent/CL2012000003A1/es
Priority to EC2012011570A priority patent/ECSP12011570A/es
Priority to ZA2012/00026A priority patent/ZA201200026B/en
Priority to NI201200002A priority patent/NI201200002A/es
Priority to CY20141100419T priority patent/CY1115626T1/el
Priority to US14/312,124 priority patent/US8993565B2/en
Priority to SM201400084T priority patent/SMT201400084B/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0957070A 2009-07-02 2009-10-09 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) Expired - Fee Related FR2951169B1 (fr)

Priority Applications (42)

Application Number Priority Date Filing Date Title
FR0957070A FR2951169B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
SG10201402867TA SG10201402867TA (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
ARP100102350A AR077364A1 (es) 2009-07-02 2010-07-01 Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
PCT/FR2010/051375 WO2011001114A1 (fr) 2009-07-02 2010-07-01 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PT107420143T PT2448927E (pt) 2009-07-02 2010-07-01 Novos derivados de (6-oxo-1,6-di-hidro-pirimidin-2-il)-amida, sua preparação e sua utilização farmacêutica como inibidores da fosforilação de akt
CA2767064A CA2767064C (fr) 2009-07-02 2010-07-01 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CN201080039214.XA CN102548970B (zh) 2009-07-02 2010-07-01 新型(6-氧代-1,6-二氢嘧啶-2-基)酰胺衍生物、其制备方法以及其作为akt(pkb)磷酸化抑制剂的医药用途
HRP20140478AT HRP20140478T1 (hr) 2009-07-02 2010-07-01 Novi derivati (6-okso-1,6-dihidropirimidin-2-il)amida, njihovo dobivanje, te farmaceutska upotreba kao inhibitora fosforilacije akt
AU2010267816A AU2010267816B2 (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
JP2012518120A JP5680638B2 (ja) 2009-07-02 2010-07-01 新規な（６−オキソ−１，６−ジヒドロピリミジン−２−イル）アミド誘導体、この調製およびａｋｔ（ｐｋｂ）リン酸化インヒビターとしてのこの医薬的な使用
MX2012000094A MX2012000094A (es) 2009-07-02 2010-07-01 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su uso farmaceutica como inhibidores de fosforilacion de akt (pkb).
SG2011097938A SG177469A1 (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
KR1020127002839A KR20120106714A (ko) 2009-07-02 2010-07-01 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도
SI201030607T SI2448927T1 (sl) 2009-07-02 2010-07-01 Novi (6-okso-1,6-dihidro-pirimidin-2-il)-amidni derivati, njihova priprava in njihova farmacevtska uporaba kot AKT fosforilacijski inhibitorji
MYPI2011006377 MY153042A (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
HK12109790.9A HK1169110B (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt phosphorylation inhibitors
PE2012000004A PE20120640A1 (es) 2009-07-02 2010-07-01 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
DK10742014.3T DK2448927T3 (da) 2009-07-02 2010-07-01 Hidtil ukendte (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amidderivater, fremstilling deraf og farmaceutisk anvendelse deraf som akt-phosphoryleringshæmmere
EA201270111A EA021088B1 (ru) 2009-07-02 2010-07-01 Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования akt (pkb)
NZ597579A NZ597579A (en) 2009-07-02 2010-07-01 Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
EP10742014.3A EP2448927B1 (fr) 2009-07-02 2010-07-01 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt
RS20140306A RS53317B (sr) 2009-07-02 2010-07-01 Novi derivati (6-okso-1,6-dihidropirimidin-2-il)amida, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora fosforilacije akt (pkb)
MEP-2014-62A ME01885B (me) 2009-07-02 2010-07-01 Novi derivati (6-0ks0-1,6-dihidropirimidin-2-il)amida, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora fosforilacije akt (pkb)
MA34593A MA33501B1 (fr) 2009-07-02 2010-07-01 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PL10742014T PL2448927T3 (pl) 2009-07-02 2010-07-01 Nowe pochodne (6-okso-1,6-dihydro-pirymidyn-2-ylo)-amidu, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT
ES10742014.3T ES2464125T3 (es) 2009-07-02 2010-07-01 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT
UY0001032755A UY32755A (es) 2009-07-02 2010-07-02 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
TW99121906A TWI466883B (zh) 2009-07-02 2010-07-02 新穎（６－側氧基－１，６－二氫嘧啶－２－基）醯胺衍生物、其製備方法及其作為ａｋｔ（ｐｋｂ）磷酸化抑制劑之醫藥用途
CR20110703A CR20110703A (es) 2009-07-02 2011-12-21 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb)
DO2011000407A DOP2011000407A (es) 2009-07-02 2011-12-26 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb)
US13/338,011 US8791255B2 (en) 2009-07-02 2011-12-27 (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
CO11180700A CO6480974A2 (es) 2009-07-02 2011-12-29 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb)
IL217295A IL217295A (en) 2009-07-02 2011-12-29 Annals of (6-oxo-1, 6-dihydropyrimidine-2-yl) amide, preparation and use of them in cancer treatment
HN2011003482A HN2011003482A (es) 2009-07-02 2011-12-30 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
IL217321A IL217321A0 (en) 2009-07-02 2012-01-01 Novel (6-oxo-1,6 - dihydro - pyrimidin - 2 - yl) - amide derivatives, prepartion thereof, and pharamaceutical use thereof as akt (pkb) phosphorylation inhibitors
CL2012000003A CL2012000003A1 (es) 2009-07-02 2012-01-02 Compuestos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida sustituida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y uso de dichos compuestos como inhibidores de fosforilacion de akt (pkb) para el tratamiento del cancer.
ZA2012/00026A ZA201200026B (en) 2009-07-02 2012-01-03 Novel (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide derivatives,preparation thereof,and pharmaceutical use thereof as akt(pkb) phosphorylation inhibotors
EC2012011570A ECSP12011570A (es) 2009-07-02 2012-01-03 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb)
NI201200002A NI201200002A (es) 2009-07-02 2012-01-05 Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
CY20141100419T CY1115626T1 (el) 2009-07-02 2014-06-11 Νεα παραγωγα (6-οξο-1,6-διυδρο-πυριμιδιν-2-υλ)-αμιδιο, η παρασκευη τους και η φαρμακευτικη χρηση τους ως αναστολεις φωσφορυλιωσης του ακτ
US14/312,124 US8993565B2 (en) 2009-07-02 2014-06-23 (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
SM201400084T SMT201400084B (it) 2009-07-02 2014-06-26 Nuovi derivati di 6-(osso-1,6diiro-pirimidin-2-il)-ammide, loro preparazione e loro uso farmaceuticocome inibitori di fosforilazione di akt

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0957070A FR2951169B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Publications (2)

Publication Number Publication Date
FR2951169A1 FR2951169A1 (fr) 2011-04-15
FR2951169B1 true FR2951169B1 (fr) 2011-12-02

Family

ID=42635139

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0957070A Expired - Fee Related FR2951169B1 (fr) 2009-07-02 2009-10-09 Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Country Status (1)

Country Link
FR (1) FR2951169B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570127A1 (fr) * 2011-09-16 2013-03-20 Sanofi Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007749A2 (fr) * 2007-07-09 2009-01-15 Astrazeneca Ab Composés 947

Also Published As

Publication number Publication date
FR2951169A1 (fr) 2011-04-15

Similar Documents

Publication Publication Date Title
FR2954317B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2485736A4 (fr) Composés de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utilisation
FR2896503B1 (fr) Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2008049116A3 (fr) Indoles substitués
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
WO2011153514A9 (fr) Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SI2658844T1 (sl) Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
SG10201402867TA (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2633862A4 (fr) Compositions à base de nanocapsules de propolis utilisables comme supports de substances d'intérêt, procédé d'obtention et utilisation
WO2009094457A3 (fr) Benzhydryléthers substitués
WO2011123524A3 (fr) Macrolides inhibiteurs de mtor
FR2941952B1 (fr) Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2969611B1 (fr) Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2951169B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947547B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
WO2010075086A3 (fr) Inhibiteurs de type pyrrolidinone de pde-4
FR2969610B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2953836B1 (fr) Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2969608B1 (fr) Nouveaux derives de (5-halo-6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2951170B1 (fr) Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160630